Intellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its price objective lowered by Chardan Capital from $94.00 to $88.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued reports about the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Stifel Nicolaus dropped their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. JPMorgan Chase & Co. lowered their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.60.

Intellia Therapeutics Stock Up 1.0 %

NASDAQ:NTLA traded up $0.16 during mid-day trading on Thursday, hitting $16.01. 467,872 shares of the stock traded hands, compared to its average volume of 1,584,704. Intellia Therapeutics has a 52 week low of $15.35 and a 52 week high of $34.87. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -2.89 and a beta of 1.76. The firm’s 50 day moving average is $20.84 and its two-hundred day moving average is $22.82.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same period in the previous year, the business earned ($1.40) EPS. Intellia Therapeutics’s revenue for the quarter was down 48.5% on a year-over-year basis. As a group, research analysts predict that Intellia Therapeutics will post -5.22 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds have recently modified their holdings of NTLA. China Universal Asset Management Co. Ltd. grew its position in Intellia Therapeutics by 72.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,537 shares of the company’s stock worth $401,000 after purchasing an additional 8,204 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics in the 3rd quarter valued at $54,000. Hennion & Walsh Asset Management Inc. raised its stake in Intellia Therapeutics by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,721 shares of the company’s stock worth $1,104,000 after acquiring an additional 13,839 shares during the last quarter. Finally, Eastern Bank acquired a new stake in Intellia Therapeutics during the 3rd quarter worth about $41,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.